|
MechanismIL-12R stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
KLT-1101与特瑞普利单抗注射液联合治疗黑色素瘤及其他实体瘤患者安全性、耐受性、PK/PD和初步疗效、开放性Ib/II期临床试验
[Translation] Safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) and preliminary efficacy of KLT-1101 in combination with toripalimab injection for the treatment of melanoma and other solid tumors; open-label phase Ib/II clinical trial.
主要目的:
评价KLT-1101与特瑞普利单抗注射液联合在黑色素瘤及其他实体瘤患者中的安全性、耐受性;
次要目的:
评价KLT-1101与特瑞普利单抗注射液联合在黑色素瘤及其他实体瘤患者中的初步疗效;
评价KLT-1101与特瑞普利单抗注射液联合在黑色素瘤及其他实体瘤患者中的药代动力学(PK)特征;
评价KLT-1101与特瑞普利单抗注射液联合在黑色素瘤及其他实体瘤患者中的免疫原性;
探索性目的:
探索KLT-1101与特瑞普利单抗注射液联合药物暴露水平与安全性的相关性;
探索KLT-1101 与特瑞普利单抗注射液联合PK/PD,以发现暴露浓度与效应细胞因子的相关性;
评价KLT-1101与特瑞普利单抗注射液联合在黑色素瘤及其他实体瘤患者中抗肿瘤疗效相关的生物标志物随时间的变化;
评价KLT-1101与特瑞普利单抗注射液联合的药物暴露水平与抗肿瘤疗效的相关性;
确定KLT-1101与特瑞普利单抗注射液联合在黑色素瘤及其他实体瘤患者中的Ⅱ期推荐剂量(RP2D) ;
[Translation] Primary Objective: To evaluate the safety and tolerability of KLT-1101 in combination with toripalimab injection in patients with melanoma and other solid tumors;
Secondary Objectives: To evaluate the preliminary efficacy of KLT-1101 in combination with toripalimab injection in patients with melanoma and other solid tumors;
To evaluate the pharmacokinetic (PK) characteristics of KLT-1101 in combination with toripalimab injection in patients with melanoma and other solid tumors;
To evaluate the immunogenicity of KLT-1101 in combination with toripalimab injection in patients with melanoma and other solid tumors;
Exploratory Objectives: To explore the correlation between drug exposure levels and safety in the combination of KLT-1101 and toripalimab injection;
To explore the effects of KLT-1101... To investigate the correlation between drug exposure concentration and effector cytokines in combination with toripalimab injection; to evaluate the changes over time in biomarkers related to the antitumor efficacy of KLT-1101 combined with toripalimab injection in patients with melanoma and other solid tumors; to evaluate the correlation between drug exposure levels and antitumor efficacy in combination with KLT-1101 combined with toripalimab injection; and to determine the phase II recommended dose (RP2D) of KLT-1101 combined with toripalimab injection in patients with melanoma and other solid tumors.
KLT-1101治疗艾滋病相关卡波西肉瘤患者的安全性、耐受性和初步疗效的Ib/II期临床试验
[Translation] Phase Ib/II clinical trial of the safety, tolerability and preliminary efficacy of KLT-1101 in patients with AIDS-related Kaposi sarcoma
主要目的:评价KLT-1101在AIDS-KS患者中的安全性、耐受性和初步疗效;确定KLT-1101在AIDS-KS患者中的II期推荐剂量(RP2D)。
次要目的:评价KLT-1101在AIDS-KS患者中的药代动力学(PK)特征;评价KLT-1101在AIDS-KS患者中的免疫原性;评价KLT-1101的药物暴露水平与抗肿瘤疗效的相关性。
探索性目的:探索KLT-1101药物暴露水平与安全性的相关性;探索KLT-1101抗肿瘤疗效相关的生物标志物随时间的变化;探索KLT-1101 PK/PD,以发现暴露浓度与效应细胞因子的相关性。
[Translation] Primary objectives: To evaluate the safety, tolerability and preliminary efficacy of KLT-1101 in AIDS-KS patients; to determine the recommended Phase II dose (RP2D) of KLT-1101 in AIDS-KS patients.
Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of KLT-1101 in AIDS-KS patients; to evaluate the immunogenicity of KLT-1101 in AIDS-KS patients; to evaluate the correlation between drug exposure level and anti-tumor efficacy of KLT-1101.
Exploratory objectives: To explore the correlation between drug exposure level and safety of KLT-1101; to explore the changes of biomarkers related to the anti-tumor efficacy of KLT-1101 over time; to explore KLT-1101 PK/PD to find the correlation between exposure concentration and effector cytokines.
KLT-1101在晚期实体瘤患者中的安全性、耐受性、药代动力学及初步疗效评价的Ib/II期临床研究
[Translation] A Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KLT-1101 in patients with advanced solid tumors
1、主要目的:评价KLT-1101在晚期实体瘤患者中的安全性和耐受性。
2、次要目的:
1) 评价KLT-1101在晚期实体瘤患者中的药代动力学特征;
2) 评价KLT-1101在晚期实体瘤患者中的药效学特征;
3) 评价KLT-1101在晚期实体瘤患者中对化疗引起的血细胞减少的疗效;
4) 评价KLT-1101在晚期实体瘤患者中的免疫原性。
3、探索性目的
1) 评价KLT-1101在晚期实体瘤患者中的抗肿瘤疗效。探索KLT-1101的临床推荐剂量.
[Translation] 1. Primary objective: To evaluate the safety and tolerability of KLT-1101 in patients with advanced solid tumors.
2. Secondary objectives:
1) To evaluate the pharmacokinetic characteristics of KLT-1101 in patients with advanced solid tumors;
2) To evaluate the pharmacodynamic characteristics of KLT-1101 in patients with advanced solid tumors;
3) To evaluate the efficacy of KLT-1101 on chemotherapy-induced hematopoiesis in patients with advanced solid tumors;
4) To evaluate the immunogenicity of KLT-1101 in patients with advanced solid tumors.
3. Exploratory objectives
1) To evaluate the anti-tumor efficacy of KLT-1101 in patients with advanced solid tumors. To explore the recommended clinical dose of KLT-1101.
100 Clinical Results associated with KANG LI TAI Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with KANG LI TAI Pharmaceutical Co., Ltd.
100 Deals associated with KANG LI TAI Pharmaceutical Co., Ltd.
100 Translational Medicine associated with KANG LI TAI Pharmaceutical Co., Ltd.